

10/531, 145

=> d his

(FILE 'HOME' ENTERED AT 15:39:32 ON 10 JAN 2008)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH, LIFESCI' ENTERED AT 15:39:54 ON 10 JAN 2008

L1 3425 S AUTOLOGOUS(4A)T(4A)LYMPHOCYTE
 L2 124385 S PBMC OR PERIPHERAL(W)BLOOD(W)MONONUCLEAR(3A)CELL
 L3 305 S L1 AND L2
 L4 4070 S (RETROVIRUS OR RETROVIRAL OR LENTIVIR? OR HIV OR MMLV)(10A)(I
 L5 2 S L3 AND L4
 L6 2 DUP REM L5 (0 DUPLICATES REMOVED)
 L7 729938 S RETROVIRUS OR RETROVIRAL OR LENTIVIR? OR HIV OR MMLV
 L8 243741 S INTERLEUKIN-2 OR IL-2
 L9 45 S L3 AND L7
 L10 12 S L8 AND L9
 L11 5 DUP REM L10 (7 DUPLICATES REMOVED)

=> d au ti so pi 1-2 16

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 IN Liu, Ke; Rosenberg, Steven A.
 TI Preparation of lymphocytes that express interleukin-2 and uses thereof in
 the treatment of cancer
 SO PCT Int. Appl., 26 pp.
 CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004034789	A1	20040429	WO 2002-US33243	20021015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501087	A1	20040429	CA 2002-2501087	20021015
AU 2002353822	A1	20040504	AU 2002-353822	20021015
EP 1558085	A1	20050803	EP 2002-789213	20021015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005233451	A1	20051020	US 2005-531145	20050519

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 AU Ennen, Joachim; Seipp, Inka; Norley, Stephen G.; Kurth, Reinhard
 TI Decreased accessory cell function of macrophages after infection with
 human immunodeficiency virus type 1 in vitro
 SO European Journal of Immunology (1990), 20(11), 2451-6
 CODEN: EJIMAF; ISSN: 0014-2980

=> d au ti so pi 1-5 111

L11 ANSWER 1 OF 5 MEDLINE on STN DUPLICATE 1
 AU Liu Shujuan; Riley John; Rosenberg Steven; Parkhurst Maria
 TI Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
 SO Journal of immunotherapy (Hagerstown, Md. : 1997), (2006 May-Jun) Vol. 29, No. 3, pp. 284-93.
 Journal code: 9706083. ISSN: 1524-9557.

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
 IN Liu, Ke; Rosenberg, Steven A.
 TI Preparation of lymphocytes that express interleukin-2
 and uses thereof in the treatment of cancer
 SO PCT Int. Appl., 26 pp.
 CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004034789	A1	20040429	WO 2002-US33243	20021015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501087	A1	20040429	CA 2002-2501087	20021015
AU 2002353822	A1	20040504	AU 2002-353822	20021015
EP 1558085	A1	20050803	EP 2002-789213	20021015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005233451	A1	20051020	US 2005-531145	20050519

L11 ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 2
 AU Ho M; Armstrong J; McMahon D; Pazin G; Huang X L; Rinaldo C; Whiteside T; Tripoli C; Levine G; Moody D; +
 TI A phase 1 study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS.
 SO Blood, (1993 Apr 15) Vol. 81, No. 8, pp. 2093-101.
 Journal code: 7603509. ISSN: 0006-4971.

L11 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 3
 AU Ennen J; Seipp I; Norley S G; Kurth R
 TI Decreased accessory cell function of macrophages after infection with human immunodeficiency virus type 1 in vitro.
 SO European journal of immunology, (1990 Nov) Vol. 20, No. 11, pp. 2451-6.
 Journal code: 1273201. ISSN: 0014-2980.

L11 ANSWER 5 OF 5 MEDLINE on STN
 AU Clerici M; Stocks N I; Zajac R A; Boswell R N; Shearer G M
 TI Accessory cell function in asymptomatic human immunodeficiency virus-infected patients.
 SO Clinical immunology and immunopathology, (1990 Feb) Vol. 54, No. 2, pp. 168-73.
 Journal code: 0356637. ISSN: 0090-1229.

=> d ab 3-5 l11

L11 ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 2
 AB Based on preclinical studies showing that CD8+ T lymphocytes of human immunodeficiency syndrome (HIV)-infected subjects have anti-HIV activities, a phase 1 study was undertaken to determine the safety and feasibility of infusing in vitro purified, activated, and expanded CD8+ cells as a therapeutic measure in seven patients with acquired immunodeficiency syndrome (AIDS)-related complex (ARC) or AIDS. Autologous CD8+ cells were first selectively isolated in monoclonal antibody-coated flasks from peripheral blood mononuclear cells recovered by leukapheresis. They were

then cultured and expanded with phytohemagglutinin and recombinant interleukin-2 (rIL-2) before infusion. Five cycles of isolations and infusions of increasing numbers of CD8+ T cells were achieved in five of seven subjects. Five cycles could not be completed in two subjects with AIDS whose CD4+ cell counts were $< \text{ or } = 48/\text{microliters}$. Infusions of CD8+ cells alone were well tolerated. Four patients received rIL-2 by continuous infusion for 5 days with their final cycle of CD8+ cells. All developed reversible adverse effects attributable to rIL-2. After infusion, 111In-labeled CD8+ cells quickly accumulated in the lungs, with less than 10% of the labeled cells remaining in the circulation. After 24 hours, labeled CD8+ cells were reduced in the lungs, but increased and persisted in liver, spleen, and bone marrow. Four of five patients who were treated with multiple infusions of CD8+ cells have improved or remained clinically stable, and the fifth developed *Pneumocystis carinii* pneumonia but recovered. This study demonstrated that infusion of autologous, in vitro expanded and activated CD8+ cells was feasible and clinically well tolerated in five of seven subjects with advanced HIV infections.

L11 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 3
 AB Peripheral blood monocytes from human immunodeficiency virus (HIV)-infected individuals or AIDS-related complex/AIDS patients ex vivo exhibit distinct alterations in some but not all immune functions. In studies presented here, monocytes from healthy donors were infected with HIV 1 in vitro and co-cultures with autologous uninfected T lymphocytes were set up. The monocyte/macrophage (M phi)-dependent T cell function was determined by measurement of proliferative and secretory [interleukin (IL) 2, interferon-gamma] responses to lectin (phytohemagglutinin), mitogen (anti-CD3 monoclonal antibody), or recall antigen (tetanus toxoid, tuberculin). Accessory function of M phi was normal after HIV infection when optimal amounts (10%-20%) were added to the T lymphocytes. However, HIV infection of M phi significantly decreased T cell proliferative responses and secretion of IL2 when supplemented at limited dilution (0.5%-5%), although interferon-gamma production was not affected. Whereas the lipopolysaccharide-triggered M phi production of IL1 was not impaired by HIV 1 infection, there was a significant decrease in this response when anti-CD3 monoclonal antibody or tetanus toxoid were used to trigger the peripheral blood mononuclear cells. The impairment of proliferation of T lymphocytes in the presence of HIV 1-infected M phi could be overcome by addition of exogenous IL 1. Taken together, these data clearly show that the mononuclear phagocyte-dependent enhancement of stimulated T cell proliferation and lymphokine secretion is decreased when the restricted numbers of monocytes/M phi are HIV 1 infected. There are, therefore, two possible roles of M phi in HIV infection and progression to disease. First, as a reservoir and vehicle for dissemination of the virus, and second, as an immune cell whose essential functions are impaired by infection.

L11 ANSWER 5 OF 5 MEDLINE on STN
 AB Peripheral blood mononuclear cells from human immunodeficiency virus seropositive (HIV+) individuals who did not exhibit symptoms of acquired immunodeficiency syndrome (AIDS) (Walter Reed Stage 1 patients) were tested for accessory cell function for presentation of recall antigens to autologous T lymphocytes and for presentation of HLA alloantigens to T lymphocytes from healthy, HIV- donors. Neither experimental model indicated a defect in accessory cell function at this early stage after HIV infection, although our study does not exclude the possibility of accessory cell dysfunction at a later stage of AIDS development.

Refine Search

Search Results -

Terms	Documents
L5 and L8	17

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L9

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Thursday, January 10, 2008
 [Purge Queries](#)
 [Printable Copy](#)
 [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=PGPB,USPT; PLUR=YES; OP=AND

<u>L9</u>	15 and L8	17	<u>L9</u>
<u>L8</u>	13 near10 14	976	<u>L8</u>
<u>L7</u>	14 and L6	206	<u>L7</u>
<u>L6</u>	13 and L5	236	<u>L6</u>
<u>L5</u>	11 and 12	310	<u>L5</u>
<u>L4</u>	interleukin-2 or il-2	35055	<u>L4</u>
<u>L3</u>	retrovirus or retroviral or lentivir\$ or hiv or mmlv	92809	<u>L3</u>
<u>L2</u>	pbmc or peripheral adj blood adj mononuclear near3 cell	16589	<u>L2</u>
<u>L1</u>	autologous near4 t near4 lymphocyte	553	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 17 of 17 returned.**

-
- ☐ 1. 20070081942. 20 Nov 06. 12 Apr 07. Gene differentially expressed in breast and bladder cancer, and encoded polypeptides. Zauderer; Maurice, et al. 424/1.49; 424/178.1 435/320.1 435/328 435/69.1 530/388.22 530/391.1 536/23.53 A61K39/395 20060101 A61K51/00 20060101 C07H21/04 20060101 C07K16/46 20060101 C12P21/06 20060101
-
- ☐ 2. 20050249711. 07 Feb 05. 10 Nov 05. Allogeneic vaccine and methods to synthesize same. Gansbacher, Bernd. 424/93.21; 424/85.2 435/372 A61K048/00 C12N005/08 A61K038/20.
-
- ☐ 3. 20050233451. 19 May 05. 20 Oct 05. Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer. Liu, Ke, et al. 435/372; C12N005/08.
-
- ☐ 4. 20050169900. 31 Mar 05. 04 Aug 05. Allogeneic vaccine and methods to synthesize same. Gansbacher, Bernd. 424/93.21; 424/85.2 424/85.6 435/369 435/456 A61K048/00 A61K038/21 C12N005/08 C12N015/867.
-
- ☐ 5. 20040063907. 10 Jun 03. 01 Apr 04. Gene differentially expressed in breast and bladder cancer and encoded polypeptides. Zauderer, Maurice, et al. 530/350; 435/320.1 435/325 435/69.1 536/23.5 C07K014/705 C07H021/04 C12P021/02 C12N005/06.
-
- ☐ 6. 20030166277. 12 Apr 01. 04 Sep 03. Targeted vaccine delivery systems. Zauderer, Maurice, et al. 435/372; 424/178.1 530/391.1 A61K039/395 C12P021/08 C07K016/46.
-
- ☐ 7. 20020155447. 04 Apr 01. 24 Oct 02. Gene differentially expressed in breast cancer, and encoded polypeptides. Zauderer, Maurice, et al. 435/6; 435/226 435/320.1 435/325 435/69.1 435/7.23 536/23.2 C12Q001/68 G01N033/574 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
-
- ☐ 8. 20010038841. 05 Jun 01. 08 Nov 01. Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine. Hiserodt, John C., et al. 424/130.1; 424/277.1 435/368 A61K039/395 A61K039/00 C12N005/08.
-
- ☐ 9. 20010036458. 05 Jun 01. 01 Nov 01. Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine. Hiserodt, John C., et al. 424/130.1; 424/277.1 435/368 A61K039/395 A61K039/00 C12N005/08.
-
- ☐ 10. 7268207. 04 Apr 01; 11 Sep 07. Gene differentially expressed in breast and bladder cancer, and encoded polypeptides. Zauderer; Maurice, et al. 530/300; 424/184.1 424/185.1 530/350. A61K38/00 20060101 C07H21/00 20060101 C07H21/02 20060101 C07H5/00 20060101 C07K14/00 20060101 C07K16/00 20060101 C07K17/00 20060101 C07K2/00 20060101 C07K4/00 20060101 C07K5/00 20060101 C08B37/00 20060101 C08B37/08 20060101 .
-
- ☐ 11. 7264820. 05 Jun 01; 04 Sep 07. Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine. Hiserodt; John C., et al. 424/277.1; A61K39/00 20060101 .
-
- ☐ 12. 6316257. 03 Mar 97; 13 Nov 01. Modified rapid expansion methods ("modified-REM") for in vitro propagation of T lymphocytes. Flyer; David C., et al. 435/372.3; 435/325 435/343.2 435/372
-

435/373 435/375 435/383 435/384 435/386 530/351 530/388.7. C12N005/08 C12N005/16 C12N005/00 C07K016/00 .

☐ 13. 6277368. 24 Jul 97; 21 Aug 01. Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine. Hiserodt; John C., et al. 424/93.21; 424/277.1 424/85.1 424/85.2 424/85.6 424/93.1 424/93.3 424/93.7 424/93.71 435/325. A01N063/00 C12N015/85 A61K035/12 A61K035/19 .

☐ 14. 6121044. 12 Jul 95; 19 Sep 00. Potent antigen presenting cell composition. Peshwa; Madhusudan Viswanath, et al. 435/325; 435/2 435/372 435/373 435/375 435/382 435/395. C12N005/00 C12N005/02 C12N005/06 .

☐ 15. 6074836. 04 Apr 96; 13 Jun 00. Method of marking eukaryotic cells. Bordinon; Claudio, et al. 435/7.24; 424/93.21 435/366 435/372.3 435/7.21. C12N005/00 G01N033/53 A01N063/00 .

☐ 16. 6040177. 13 Mar 96; 21 Mar 00. High efficiency transduction of T lymphocytes using rapid expansion methods ("REM"). Riddell; Stanley R., et al. 435/372.3; 435/2 435/320.1 435/373 435/374 435/375 435/377 435/383 435/384 435/455 530/351 530/388.75 536/23.1 536/23.72. C12N005/10 C12N015/11 C07K014/55 C07K016/28 .

☐ 17. 5827642. 03 Oct 94; 27 Oct 98. Rapid expansion method ("REM") for in vitro propagation of T lymphocytes. Riddell; Stanley R., et al. 435/2; 424/93.71 435/372.3 435/373 435/375 435/383 435/384 435/386. C12N005/02 C12N005/08 A01N001/02 A61K035/12 .

[Generate Collection](#)

[Print](#)

Terms	Documents
L5 and L8	17

[Prev Page](#)

[Next Page](#)

[Go to Doc#](#)